Aldeyra Therapeutics Company Profile (NASDAQ:ALDX)

About Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALDX
  • CUSIP: N/A
  • Web: www.aldeyra.com
Capitalization:
  • Market Cap: $141.36 million
  • Outstanding Shares: 6,245,000
Average Prices:
  • 50 Day Moving Avg: $4.93
  • 200 Day Moving Avg: $4.79
  • 52 Week Range: $3.80 - $11.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.34
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.54 per share
  • Price / Book: 4.94
Profitability:
  • EBIDTA: ($19,820,000.00)
  • Return on Equity: -80.41%
  • Return on Assets: -70.58%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 12.48%
  • Quick Ratio: 12.48%
Misc:
  • Average Volume: 612,786 shs.
  • Beta: 0.33
  • Short Ratio: 2.46
 

Frequently Asked Questions for Aldeyra Therapeutics (NASDAQ:ALDX)

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced its earnings results on Tuesday, August, 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.37) by $0.02. View Aldeyra Therapeutics' Earnings History.

When will Aldeyra Therapeutics make its next earnings announcement?

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Aldeyra Therapeutics.

Where is Aldeyra Therapeutics' stock going? Where will Aldeyra Therapeutics' stock price be in 2017?

4 brokerages have issued 1 year target prices for Aldeyra Therapeutics' shares. Their forecasts range from $14.00 to $27.00. On average, they expect Aldeyra Therapeutics' share price to reach $18.75 in the next year. View Analyst Ratings for Aldeyra Therapeutics.

What are analysts saying about Aldeyra Therapeutics stock?

Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (8/17/2017)
  • 2. Cowen and Company analysts commented, "On its 4Q call, ALDX announced the Feb start of the planned ADX-102 Ph2b allergic." (3/31/2017)

Who are some of Aldeyra Therapeutics' key competitors?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the folowing people:

  • Todd Brady M.D., President, Chief Executive Officer, Director
  • Stephen J. Tulipano CPA, Chief Financial Officer, Treasurer
  • Scott L Young, Chief Operating Officer
  • David J. Clark M.D., Chief Medical Officer
  • Ben Bronstein M.D., Director
  • Jesse I. Treu Ph.D., Director
  • Richard H. Douglas Ph.D., Independent Director
  • Martin J. Joyce, Independent Director
  • Gary M. Phillips M.D., Independent Director

Who owns Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (26.49%), Sphera Funds Management LTD. (14.03%), Vanguard Group Inc. (4.88%), Hikari Power Ltd (1.73%) and Virtu KCG Holdings LLC (0.36%). Company insiders that own Aldeyra Therapeutics stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

Who sold Aldeyra Therapeutics stock? Who is selling Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. View Insider Buying and Selling for Aldeyra Therapeutics.

Who bought Aldeyra Therapeutics stock? Who is buying Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Hikari Power Ltd, Virtu KCG Holdings LLC and Vanguard Group Inc.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

How do I buy Aldeyra Therapeutics stock?

Shares of Aldeyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of Aldeyra Therapeutics stock can currently be purchased for approximately $7.60.


MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  214
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aldeyra Therapeutics (NASDAQ:ALDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.75 (146.71% upside)

Analysts' Ratings History for Aldeyra Therapeutics (NASDAQ:ALDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Cowen and CompanyReiterated RatingOutperform$9.00 -> $14.00HighView Rating Details
9/13/2017Canaccord GenuityReiterated RatingBuy -> Buy$12.00 -> $27.00MediumView Rating Details
8/9/2017HC WainwrightSet Price TargetBuy$18.00LowView Rating Details
5/31/2017Stifel NicolausReiterated RatingBuy$16.00MediumView Rating Details
2/29/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)
Earnings by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Earnings History by Quarter for Aldeyra Therapeutics (NASDAQ ALDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.41)N/AView Earnings Details
8/8/2017Q2 2017($0.37)($0.35)ViewListenView Earnings Details
5/15/2017Q1 2017($0.33)($0.37)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.66)($0.36)ViewN/AView Earnings Details
11/14/2016Q316($0.39)($0.38)ViewN/AView Earnings Details
8/10/2016Q216($0.44)($0.41)ViewListenView Earnings Details
5/9/2016Q116($0.50)($0.51)ViewN/AView Earnings Details
11/12/2015Q315($0.29)($0.35)ViewListenView Earnings Details
8/11/2015Q215($0.35)($0.27)ViewListenView Earnings Details
5/13/2015Q115($0.39)($0.32)ViewListenView Earnings Details
4/14/2015($0.39)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.32)($0.36)ViewN/AView Earnings Details
8/4/2014Q214($0.53)($1.56)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)
Current Year EPS Consensus Estimate: $-1.67 EPS
Next Year EPS Consensus Estimate: $-1.75 EPS

Dividends

Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aldeyra Therapeutics (NASDAQ:ALDX)
Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 49.09%
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2017Life Sciences Maste PerceptiveMajor ShareholderBuy200,000$7.25$1,450,000.00View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy296,007$4.60$1,361,632.20View SEC Filing  
2/17/2017Martin Joseph JoyceDirectorBuy4,444$4.50$19,998.00View SEC Filing  
2/17/2017Stephen J TulipanoCFOBuy3,333$4.50$14,998.50View SEC Filing  
2/17/2017Todd C BradyInsiderBuy22,223$4.50$100,003.50View SEC Filing  
2/14/2017Perceptive Advisors LlcMajor ShareholderBuy893,025$4.50$4,018,612.50View SEC Filing  
5/26/2016Perceptive Advisors LlcMajor ShareholderBuy700,000$5.00$3,500,000.00View SEC Filing  
10/26/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.46$323,000.00View SEC Filing  
10/22/2015Perceptive Advisors LlcMajor ShareholderBuy18,020$6.47$116,589.40View SEC Filing  
10/20/2015Perceptive Advisors LlcMajor ShareholderBuy37,145$6.39$237,356.55View SEC Filing  
8/7/2014Martin Joseph JoyceDirectorBuy1,000$3.95$3,950.00View SEC Filing  
8/6/2014C. Boyd ClarkeDirectorBuy3,000$3.69$11,070.00View SEC Filing  
5/7/2014C. Boyd ClarkeDirectorBuy12,500$8.00$100,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aldeyra Therapeutics (NASDAQ:ALDX)
Latest Headlines for Aldeyra Therapeutics (NASDAQ:ALDX)
Source:
DateHeadline
finance.yahoo.com logoAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - September 22 at 2:47 PM
americanbankingnews.com logoLife Sciences Maste Perceptive Purchases 200,000 Shares of Aldeyra Therapeutics, Inc. (ALDX) Stock
www.americanbankingnews.com - September 21 at 10:26 AM
finance.yahoo.com logoAldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 3:39 PM
benzinga.com logoMid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations - Benzinga
www.benzinga.com - September 19 at 3:44 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Prices 3.45M Common Stock Offering at $7.25/Share - StreetInsider.com
www.streetinsider.com - September 19 at 3:43 PM
seekingalpha.com logoAldeyra Therapeutics: Secondary Offering Clears Key Overhang - Seeking Alpha
seekingalpha.com - September 19 at 3:43 PM
finance.yahoo.com logoAldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 19 at 3:43 PM
seekingalpha.com logoAldeyra Therapeutics: Transitioning Into A Promising Late-Stage Story - Seeking Alpha
seekingalpha.com - September 18 at 9:10 PM
seekingalpha.com logoAldeyra Finally Gets The Recognition It Deserves - Seeking Alpha
seekingalpha.com - September 18 at 9:10 PM
finance.yahoo.com logoAldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 18 at 4:08 PM
americanbankingnews.com logo Brokerages Anticipate Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - September 17 at 12:30 AM
seekingalpha.com logoAldeyra Spikes On 'Significant Improvements' In Midstage Dry Eye Study - Seeking Alpha
seekingalpha.com - September 16 at 3:35 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals
finance.yahoo.com - September 15 at 4:04 PM
americanbankingnews.com logoAldeyra Therapeutics' (ALDX) "Outperform" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - September 14 at 9:08 AM
streetinsider.com logoPre-Open Stock Movers 09/13: (SNAK) (ALDX) (JWN) Higher; (DCTH) (AMRK) (WDC) Lower (more...)
www.streetinsider.com - September 14 at 2:55 AM
seekingalpha.com logoAldeyra Therapeutics (ALDX) Presents On Dry Eye Disease Phase 2a Results - Slideshow
seekingalpha.com - September 14 at 2:55 AM
rttnews.com logoAldeyra Therapeutics Inc. (ALDX) Jumped To A 5-Month High On Study Results
www.rttnews.com - September 13 at 4:53 PM
finance.yahoo.com logoAldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
finance.yahoo.com - September 13 at 4:53 PM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (ALDX) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 13 at 8:36 AM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (ALDX) Upgraded at ValuEngine
www.americanbankingnews.com - September 12 at 11:56 PM
nasdaq.com logoMid-Afternoon Market Update: Sage Therapeutics Drops After Brexanolone Drug Fails Phase III Testing; Aldeyra Therapeutics Shares Gain
www.nasdaq.com - September 12 at 8:59 PM
rttnews.com logoAldeyra Therapeutics Inc. (ALDX) Has Jumped To A 9-Month High On Study Results
www.rttnews.com - September 12 at 8:59 PM
finance.yahoo.com logoAldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - September 12 at 3:57 PM
finance.yahoo.com logoAldeyra Therapeutics' stock soars after positive results of dry eye disease treatment
finance.yahoo.com - September 12 at 3:57 PM
finance.yahoo.com logoAldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers
finance.yahoo.com - September 12 at 3:56 PM
finance.yahoo.com logoAldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - September 11 at 4:34 PM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (ALDX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 6 at 2:50 AM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (ALDX) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - August 29 at 12:10 PM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (ALDX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 17 at 6:50 PM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (ALDX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 10 at 8:28 PM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (ALDX) Issues Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - August 9 at 4:34 PM
finance.yahoo.com logoAldeyra Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 3:38 PM
finance.yahoo.com logoAldeyra Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
finance.yahoo.com - August 3 at 3:47 PM
finance.yahoo.com logoAldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 4:42 PM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (NASDAQ:ALDX) to Release Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Will Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - July 21 at 10:20 PM
finance.yahoo.com logoAldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - July 18 at 5:11 PM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Major Shareholder Life Sciences Maste Perceptive Buys 296,007 Shares
www.americanbankingnews.com - July 5 at 7:06 PM
americanbankingnews.com logoZacks: Brokerages Expect Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - June 27 at 6:23 PM
finance.yahoo.com logoAldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting
finance.yahoo.com - June 19 at 3:30 PM
americanbankingnews.com logoCanaccord Genuity Analysts Give Aldeyra Therapeutics, Inc. (ALDX) a $12.00 Price Target
www.americanbankingnews.com - June 15 at 11:20 PM
rttnews.com logoKeep An Eye On ALDX Today
www.rttnews.com - June 15 at 1:31 AM
finance.yahoo.com logoAldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing
finance.yahoo.com - June 14 at 3:29 PM
finance.yahoo.com logoAldeyra Therapeutics stock drops 16% after mid-stage trial miss
finance.yahoo.com - June 14 at 3:29 PM
finance.yahoo.com logoAldeyra Stumbles Over Mid-Stage Clinical Results
finance.yahoo.com - June 14 at 3:29 PM
finance.yahoo.com logoAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial
finance.yahoo.com - June 13 at 8:29 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Says First Patient Enrolled in Dry Eye Disease Phase 2a Trial
www.streetinsider.com - June 8 at 9:09 PM
finance.yahoo.com logoAldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - June 6 at 9:51 AM
streetinsider.com logoAldeyra Therapeutics (ALDX) Enters $20M ATM Offering Agreement
www.streetinsider.com - June 3 at 2:38 AM
americanbankingnews.com logoZacks: Analysts Anticipate Aldeyra Therapeutics Inc (ALDX) to Post -$0.41 Earnings Per Share
www.americanbankingnews.com - June 1 at 2:22 PM

Social

Chart

Aldeyra Therapeutics (ALDX) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff